Premium
Circulating chemokine (C‐X‐C Motif) receptor 5 + CD4 + T cells benefit hepatitis B e antigen seroconversion through IL‐21 in patients with chronic hepatitis B virus infection
Author(s) -
Li Yongyin,
Ma Shiwu,
Tang Libo,
Li Yun,
Wang Wei,
Huang Xuan,
Lai Qintao,
Zhang Mingxia,
Sun Jian,
Li Chris Kafai,
Abbott William G.H.,
Naoumov Nikolai V.,
Zhang Yu,
Hou Jinlin
Publication year - 2013
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.26489
Subject(s) - seroconversion , virology , medicine , chronic hepatitis , chemokine , virus , hepatitis b antigens , antigen , hepatitis b virus , immunology , immune system
Given the clinical significance of hepatitis B e antigen (HBeAg) seroconversion in chronic hepatitis B virus (HBV) infection, it is critical to elucidate the mechanisms regulating this process. In the present study, we found that the frequency of circulating chemokine (C‐X‐C motif) receptor 5 (CXCR5) + CD4 + T cells was higher in patients who had achieved HBeAg seroconversion in both cross‐sectional ( P < 0.001) and longitudinal ( P = 0.009) studies. These cells were able to produce a significantly higher level of intracellular interleukin 21 (IL‐21) after stimulation with HBV peptides in patients with telbivudine‐induced HBeAg seroconversion ( P = 0.007). Furthermore, sorted CXCR5 + CD4 + T cells from HBeAg seroconverters boosted a higher frequency of antibody against hepatitis B e antigen (anti‐HBe)‐secreting B cells in coculture assay ( P = 0.011). Of note, the increase in frequency of anti‐HBe‐secreting B cells was abrogated by soluble recombinant IL‐21 receptor‐Fc chimera ( P = 0.027), whereas exogenous recombinant IL‐21 enhanced this effect ( P = 0.043). Additionally, circulating CXCR5 + CD4 + T cells shared similar phenotypic markers, and were positively correlated in frequency with, splenic follicular T helper cells. Conclusion : Circulating CXCR5 + CD4 + T cells, by producing IL‐21, may have a significant role in facilitating HBeAg seroconversion in patients with chronic HBV infection. (H epatology 2013;58:1277–1286)